Ticagrelor 90 mg
Ticagrelor 90 mg is a pharmaceutical drug with 19 clinical trials. Currently 10 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
0
Mid Stage
18
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
10
trials recruiting
19
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
One-Month DAPT in CABG Patients
Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA
TADCLOT- a Double Blind Randomized Controlled Trial
Clinical Trials (19)
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
One-Month DAPT in CABG Patients
Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA
TADCLOT- a Double Blind Randomized Controlled Trial
Ticagrelore Alone Post PCI
Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA
Combining Aspirin With Ticagrelor or Cilostazol in Minor Stroke or TIA
Ticagrelor Versus Cilostazol in Minor Ischemic Stroke or TIA
Ticagrelor Versus Cilostazol in Large-vessel Ischemic Stroke
Ticagrelor Versus Cilostazol in Ischemic Stroke
Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke
Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study
Switching From Ticagrelor to Prasugrel in Patients With Acute Coronary Syndrome
ADHERE-S (NIS Brilique)
Clopidogrel And Ticagrelor in Healthy Subjects
Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation
Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
All 19 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 19